Current Footprint - Bioflux®
Portfolio of complementary technologies:
- Biotres ® - FDA cleared
- Bioheart ® - consumer product currently in initial production
- Biocare® App – about to go through field testing
- Bioflux® 2 – in alpha prototyping
Large Scale production in place.
Medicare Reimbursement in place.
Cardiologists across 29 states use the Bioflux daily.
Currently have over 500 centers across 29 states: focused on expanding salesforce to expand footprint.
Our sales force is comprised of seasoned professionals, each with a proven track record of introducing disruptive cardiovascular technologies to the marketplace.
Use a proprietary data tool to identify target markets within the US, based on CMS reimbursement data.
More Key Details From The Company Presentation.
And as I mentioned above, BTCY has 5 potential catalysts that could provide it with a breakout spark. Here they are:
No. 1 BTCY Potential Catalyst - Zacks Small-Cap Research Provides $7.50 Price Target
In 2022, BTCY was tagged with a strong target from Zacks Small-Cap Research that is providing this profile with over 700% potential upside from Wednesday's closing valuation.
Here's some key details from the report:
We are optimistic about the outlook for BTCY’s technology and ecosystem as the company expands both distribution and its product and service offerings. At this early stage in its development, it is difficult to compare BTCY to other companies on traditional valuation metrics such as P/E or EV/ EBITDA, in our view. We therefore value BTCY shares using a peer comparables valuation methodology based on EV/Sales.
We appreciate the company’s runway and addressable market for additional penetration of its network for Bioflux, the Biotres launch contribution and the recurring revenues stream and shift in the sales mix towards higher margin TaaS over time. We therefore think the current share price level does not reflect the fundamental value of the company’s prospects. As the company continues to advance its strategy, we would anticipate multiple and share price expansion. We believe accelerating revenue ramp as both Bioflux and Biotres gain traction could be catalysts.
Although the revenue arc for BTCY is somewhat unclear at this stage because of many variables, including whether the pandemic has a lingering impact and global logistics challenges, we believe it reasonable to project that BTCY can attain revenue in the $40-$45Mn range by FY25-FY26. We reach $7.50 valuation per share based on peer group median of 9.0x EV/sales applied to this anticipated range, which includes a ramp-up in contribution from Biotres, Bioflux and other offerings in development.
No. 2 BTCY Potential Catalyst - 2023 Sales Could Grow Significantly With Signing Of New Distribution Agreement
Biotricity Signs with Top 5 Group Purchasing Organization; Potential for Higher Sales Volume in 2023
REDWOOD CITY, CA / ACCESSWIRE / January 17, 2023 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, announced it has signed an agreement with a leading group purchasing organization ("GPO") for national distribution of its cardiac monitoring solutions, Bioflux® and BiotresTM.
Both Bioflux and Biotres are designed for cardiologists to diagnose and monitor their patients remotely. GPO's are entities comprised of businesses organized to purchase materials or supplies from vendors in larger volumes to gain efficiency. In this case, the GPO is comprised of hundreds of small, independent US hospitals, private clinics, and medical offices that purchase medical devices and supplies at scale.
"Becoming a newly featured vendor of state-of-the-art cardiac monitoring solutions with a leading medical device & supplies GPO, will boost our visibility industry-wide," said Waqaas Al-Siddiq, Ph.D., Biotricity Founder, Chairman and CEO. "We anticipate increasing revenue growth across 2023 through the expansion of our products' availability through these new sales channels."
Read the full article here.
No. 3 BTCY Potential Catalyst - A Massive Revenue Growth Announcement Highlights A Company On The Rise
Biotricity Surpasses $10Mn in Annual Revenue Run Rate
Company Delivers Revenue Growth in 9 Out of the last 10 Consecutive Quarters
REDWOOD CITY, CA / ACCESSWIRE / November 21, 2022 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, today announced it has surpassed $10Mn in annual revenue run rate.
"With strong revenue growth each quarter, our scale and market reach increases every day," says Biotricity Founder and CEO, Dr. Waqaas Al-Siddiq. "I am committed to continuing to drive growth and realize our potential. Our focus remains on providing the cardiac health market with disruptive, superior digital and AI technology at competitive pricing with unrivaled support to our customers and physician partnerships."
Biotricity boasts multiple ground-breaking products including Bioflux®, Biotres, and Bioheart which won TIME's Best Inventions of 2022.
- Bioflux: a high-precision, single-unit mobile cardiac telemetry (MCT) device that provides real-time monitoring and transmission of your ECG information to your doctor
- Biotres: an easy to wear, rechargeable device with wireless capability, utilizing the advanced technology of the Bioflux® for more active days
- Bioheart: a consumer-targeted continuous heart rhythm monitor that uses the most advanced heart technology to deliver unlimited heart data insights with three views of your heart
The record revenue run rate is Biotricity's latest achievement in a string of major milestones that include:
- The Company's Bioheart personal cardiac monitor won TIME's Best Inventions of 2022
- Awarded $250K NIH grant from the National Heart, Blood, and Lung Institute for AI-enabled real-time monitoring and predictive analytics for stroke due to chronic kidney failure
- Surpassed 2 billion recorded and analyzed heartbeats for atrial fibrillation (A-fib)
- Company has delivered revenue growth in nine out of the last ten consecutive quarters
Read the full article here.
No. 4 BTCY Potential Catalyst - A Low Float Provides Volatility Potential On A Daily Basis
According to the Yahoo Finance website, BTCY has a relatively low float.
The website reports this profile to have approximately 38.92Mn shares in its float.
Why is that important? It's important on one crucial level. Volatility.
Could positive company news early in 2023 provide a near term spark?
No. 5 BTCY Potential Catalyst - Company's Device Added To Prestigious TIME Magazine List
Biotricity's Bioheart Named to TIME's List of The Best Inventions of 2022
Bioheart provides consumers the most advanced personal heart monitoring technology, combining powerful analytics and continuous heart monitoring for personalized heart insights
REDWOOD CITY, CA / ACCESSWIRE / November 10, 2022 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, today announced that its Bioheart device has been named to TIME's list of the Best Inventions of 2022. Bioheart is the first of its kind - a continuous heart rhythm monitor using advanced technology to deliver unlimited heart data insights.
Cardiac issues are intermittent, often asymptomatic, and lifelong in nature, requiring continuous heart activity monitoring. Fitness trackers simply collect your heart rate and personal ECG devices manually collect a few minutes of data, leaving you without the full picture. Bioheart changes everything by creating the first heart activity monitor. Whether you are sleeping, sitting, or out exploring the world, Bioheart's uninterrupted monitoring keeps you informed about your heart 24/7.
TIME reveals its annual list of the Best Inventions, which features 200 extraordinary innovations changing our lives: time.com/best-inventions-2022. To compile the list, TIME solicited nominations from TIME's editors and correspondents around the world, as well as through an online application process, paying special attention to growing fields-such as the electric vehicle industry, green energy, and the metaverse. TIME then evaluated each contender on a number of key factors, including originality, efficacy, ambition, and impact.
Of the New Best Inventions list, TIME's editors wrote: "The result is a list of 200 groundbreaking inventions (and 50 special mention inventions)- including life-mapping artificial intelligence, diamonds made from excess carbon in the air, and the most powerful telescope ever-that are changing how we live, work, play, and think about what's possible."
"We are honored and excited to have our premier consumer product, Bioheart, included in TIME's 2022 list," commented Dr. Waqaas Al-Siddiq, Founder and CEO of Biotricity. "Our mission is to disrupt and transform the state of cardiac health and wellness, worldwide. Bioheart is the beginning of this journey."
Read the full article here.
BTCY Recap - The 5 Top Potential Breakout Catalysts To Know
No. 1 - Zacks Small-Cap Research Provides $7.50 Price Target
No. 2 - 2023 Sales Could Grow Significantly With Signing Of New Distribution Agreement
No. 3 - A Massive Revenue Growth Announcement Highlights A Company On The Rise
No. 4 - A Low Float Provides Volatility Potential On A Daily Basis
No. 5 - Company's Device Added To Prestigious TIME Magazine List
Coverage is officially reinitiated on BTCY. When time permits, do this: